LYFE Sciences · Project HERA
Variant Interpretation · Classification Report
Generated: 2026-11-17
Case ID: NM_007294.4_c.231G_A_20261117_164643
Framework: ACMG/AMP 2015 with ENIGMA Table 3 adaptations
Variant classification summary

NM_007294.4:c.231G>A

BRCA1  · NP_009225.1:p.(Thr77=)  · NM_007294.4
GRCh37: chr17:41256955 C>T  ·  GRCh38: chr17:43104938 C>T
Gene: BRCA1 Transcript: NM_007294.4
Final call
Likely Benign
BP4 supporting BP5 supporting BP7 supporting
All criteria require review: For research and educational purposes only.
Gene
BRCA1
Transcript
NM_007294.4
Protein
NP_009225.1:p.(Thr77=)
gnomAD AF
3.7181355780957195e-06 (v4.1)
ClinVar
Likely benign
OncoKB
Interpretation summary
Generated evidence synthesis
1
BP4 Supporting: synonymous p.(Thr77=) in the RING domain with SpliceAI maximum delta score 0.052.
2
BP5 Supporting: multifactorial clinical-history LR 0.3544 falls within the ENIGMA benign-supporting range.
3
BP7 Supporting: silent variant in the RING domain with BP4 met, satisfying the ENIGMA BP7 rule.
Final determination: Under ENIGMA Table 3, at least two Supporting benign criteria satisfy Likely Benign; BP4, BP5, and BP7 provide three Supporting benign criteria, while no pathogenic rule is satisfied.
ACMG/AMP criteria review
Criteria shown when status is available
All criteria require review: For research and educational purposes only.
Criterion Status Rationale Evidence used
PVS1 N/A Not applicable: c.231G>A is synonymous (p.Thr77=), not one of the VCEP-defined null variants, and SpliceAI max delta 0.052 is below 0.2.
cspec pvs1_variant_assessment spliceai vcep_specifications_table4_v1_2_2024_11_18
PS1 N/A Not applicable: c.231G>A is synonymous, and SpliceAI max delta 0.052 is below the VCEP's 0.1 no-splicing threshold.
cspec vcep_specifications_v1_2_2024_11_18
PS2 N/A Not applicable: the BRCA1 VCEP explicitly says PS2 should not be used because de novo cancer occurrences lack calibration.
cspec
PS3 Not assessed Not assessed: no exact c.231G>A functional-assay entry or pre-assigned PS3 code was found in the governing ENIGMA datasets.
vcep_specifications_table9_v1_2_2024_11_18 vcep_supplementarytables_v1_2_2024_11_18 vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_humu_40_1557_s001
PS4 Not met Not met: no variant-specific case-control counts, odds ratio, p-value, or confidence interval establish the VCEP requirements of p≤0.05, OR≥4, and lower CI>2.0.
cspec vcep_specifications_v1_2_2024_11_18 PMID:23788249
PM1 N/A Not applicable: the ENIGMA VCEP explicitly says PM1 is not used and treats this evidence within PP3/BP4 instead.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18
PM2 Not met Not met: gnomAD v2.1 non-cancer exomes contains one allele (AF 4.22504e-06), and the VCEP says a single observation is not informative.
cspec vcep_appendices_v1_2_2024_11_18 gnomad_v2
PM3 Not assessed Not assessed: no documented same-gene pathogenic variant, phase, or Fanconi Anemia phenotype is available to assign PM3 points.
cspec
PM4 N/A Not applicable: the variant causes no protein-length change, and the VCEP explicitly marks PM4 Do not use.
cspec vcep_specifications_v1_2_2024_11_18
PM5 N/A Not applicable: c.231G>A is synonymous, while VCEP PM5 is not used for missense changes and PM5(PTC) requires a PVS1 protein-termination variant.
cspec vcep_specifications_v1_2_2024_11_18 vcep_specifications_table4_v1_2_2024_11_18
PM6 N/A Not applicable: the BRCA1 VCEP explicitly says PM6 should not be used because de novo cancer occurrences lack calibration.
cspec
PP1 Not assessed Not assessed: no quantitative co-segregation LR, affected-family pedigree, or informative meioses are available for this variant.
cspec
PP2 N/A Not applicable: the VCEP explicitly says PP2 is not used because BRCA1 has a high frequency of benign missense variants.
cspec vcep_specifications_v1_2_2024_11_18
PP3 Not met Not met: SpliceAI maximum delta score 0.052 is below the VCEP PP3 threshold of 0.2 for predicted splicing in silent variants.
cspec vcep_specifications_v1_2_2024_11_18 spliceai vcep_supplementarytables_v1_2_2024_11_18 vcep_specifications_table9_v1_2_2024_11_18 PMID:22505045
PP4 Not met Not met: Li et al. report LR 0.354419980849377, and 0.354419980849377 ≥ 2.08? no, below the VCEP PP4 Supporting threshold.
cspec vcep_specifications_v1_2_2024_11_18 vcep_pmid_31853058_brca1_clinical_history_lr PMID:31853058
PP5 N/A Not applicable: the ENIGMA VCEP prohibits PP5, so no reputable-source classification can be used for this criterion.
cspec vcep_specifications_v1_2_2024_11_18
BA1 Not assessed Not assessed: the governing rule requires non-founder FAF above 0.001 and at least 20× read depth, but neither FAF nor depth is reported.
cspec vcep_appendices_v1_2_2024_11_18 gnomad_v2
BS1 Not assessed Not assessed: the governing rule requires non-founder FAF above 0.00002 and at least 20× read depth, but neither FAF nor depth is reported.
cspec vcep_appendices_v1_2_2024_11_18 gnomad_v2
BS2 Not assessed Not assessed: no phenotyped clinical-cohort co-occurrence or homozygote observation meeting the VCEP's Fanconi-Anemia-unaffected points table is available.
cspec vcep_appendices_v1_2_2024_11_18
BS3 Not assessed Not assessed: no exact c.231G>A functional-assay entry or pre-assigned BS3 code was found in the governing ENIGMA datasets.
vcep_specifications_table9_v1_2_2024_11_18 vcep_supplementarytables_v1_2_2024_11_18 vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 vcep_humu_40_1557_s001
BS4 Not assessed Not assessed: no quantitative non-segregation LR, affected-family pedigree, or informative meioses are available for this variant.
cspec
BP1 Not met Not met: SpliceAI max delta 0.052 meets the ≤0.1 condition, but residue 77 is inside the BRCA1 RING domain spanning aa 2-101.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18
BP2 N/A Not applicable: the ENIGMA specification explicitly states that BP2 is not to be used.
cspec
BP3 N/A Not applicable: c.231G>A is synonymous, not an in-frame indel, and the VCEP explicitly marks BP3 Do not use.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18
BP4 Met Met at Supporting: SpliceAI maximum delta score 0.052 is below the VCEP BP4 threshold of 0.1 for a silent variant inside the RING domain.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 spliceai vcep_supplementarytables_v1_2_2024_11_18 vcep_specifications_table9_v1_2_2024_11_18 PMID:22505045
BP5 Met Met at Supporting: Li et al. report LR 0.354419980849377, satisfying 0.354419980849377 ≤ 0.48 and >0.23 under the VCEP BP5 range.
cspec vcep_specifications_v1_2_2024_11_18 vcep_pmid_31853058_brca1_clinical_history_lr PMID:31853058
BP6 Met Not applicable: the ENIGMA VCEP prohibits BP6, so no reputable-source benign report can be used for this criterion.
cspec vcep_specifications_v1_2_2024_11_18 clinvar
BP7 Met Met at Supporting: the silent p.(Thr77=) variant meets BP4 with SpliceAI maximum delta score 0.052, satisfying the VCEP BP7 condition.
cspec vcep_specifications_v1_2_2024_11_18 vcep_appendices_v1_2_2024_11_18 spliceai vcep_supplementarytables_v1_2_2024_11_18 vcep_specifications_table9_v1_2_2024_11_18 PMID:22505045
Disclaimer: The content and results provided by LYFE Sciences are for research and educational purposes only and must not be used as a substitute for professional medical judgment, diagnosis, or treatment. Always consult a qualified healthcare professional before making any clinical decisions.